Global Biosimilars Market Research Report 2019


Report ID : RC-4933 Category : Pharmaceuticals Published Date : Jan-2019
Publisher : QYResearch Pages : 117 Format : PDF
This report studies the global market size of Biosimilars in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilars in these regions.
This research report categorizes the global Biosimilars market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
In 2017, the global Biosimilars market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Biosimilars market based on company, product type, application and key regions.
The various contributors involved in the value chain of Biosimilars include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Biosimilars include
    Pfizer
    Sandoz International GmbH
    Teva Pharmaceuticals Industries
    Amgen Inc
    Biocon
    Dr. Reddy’s Laboratories
    F. Hoffmann-La Roche
    Celltrion
    Samsung Bioepis
Market Size Split by Type
    Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
    Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)
    Peptides (Glucagon, Calcitonin)
Market Size Split by Application
    Oncology
    Blood Disorders
Market size split by Region
    North America
        United States
        Canada
        Mexico
    Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Malaysia
        Philippines
        Thailand
        Vietnam
    Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
    Central & South America
        Brazil
        Rest of Central & South America
    Middle East & Africa
        GCC Countries
        Turkey
        Egypt
        South Africa
The study objectives of this report are:
    To study and analyze the global Biosimilars market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
    To understand the structure of Biosimilars market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Biosimilars manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Biosimilars with respect to individual growth trends, future prospects, and their contribution to the total market.
    To project the value and volume of Biosimilars submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Biosimilars are as follows:
    History Year: 2013-2017
    Base Year: 2017
    Estimated Year: 2018
    Forecast Year 2018 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biosimilars market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents
1 Study Coverage

    1.1 Biosimilars Product

    1.2 Key Market Segments

    1.3 Key Manufacturers Covered

    1.4 Market by Type

        1.4.1 Global Biosimilars Market Size Growth Rate by Type

        1.4.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

        1.4.3 Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)

        1.4.4 Peptides (Glucagon, Calcitonin)

    1.5 Market by Application

        1.5.1 Global Biosimilars Market Size Growth Rate by Application

        1.5.2 Oncology

        1.5.3 Blood Disorders

    1.6 Study Objectives

    1.7 Years Considered

2 Executive Summary

    2.1 Global Biosimilars Market Size

        2.1.1 Global Biosimilars Revenue 2016-2025

        2.1.2 Global Biosimilars Sales 2016-2025

    2.2 Biosimilars Growth Rate by Regions

        2.2.1 Global Biosimilars Sales by Regions

        2.2.2 Global Biosimilars Revenue by Regions

3 Breakdown Data by Manufacturers

    3.1 Biosimilars Sales by Manufacturers

        3.1.1 Biosimilars Sales by Manufacturers

        3.1.2 Biosimilars Sales Market Share by Manufacturers

        3.1.3 Global Biosimilars Market Concentration Ratio (CR5 and HHI)

    3.2 Biosimilars Revenue by Manufacturers

        3.2.1 Biosimilars Revenue by Manufacturers (2016-2018)

        3.2.2 Biosimilars Revenue Share by Manufacturers (2016-2018)

    3.3 Biosimilars Price by Manufacturers

    3.4 Biosimilars Manufacturing Base Distribution, Product Types

        3.4.1 Biosimilars Manufacturers Manufacturing Base Distribution, Headquarters

        3.4.2 Manufacturers Biosimilars Product Category

        3.4.3 Date of International Manufacturers Enter into Biosimilars Market

    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type

    4.1 Global Biosimilars Sales by Type

    4.2 Global Biosimilars Revenue by Type

    4.3 Biosimilars Price by Type

5 Breakdown Data by Application

    5.1 Overview

    5.2 Global Biosimilars Breakdown Data by Application

6 North America

    6.1 North America Biosimilars by Countries

        6.1.1 North America Biosimilars Sales by Countries

        6.1.2 North America Biosimilars Revenue by Countries

        6.1.3 United States

        6.1.4 Canada

        6.1.5 Mexico

    6.2 North America Biosimilars by Type

    6.3 North America Biosimilars by Application

    6.4 North America Biosimilars by Company

7 Europe

    7.1 Europe Biosimilars by Countries

        7.1.1 Europe Biosimilars Sales by Countries

        7.1.2 Europe Biosimilars Revenue by Countries

        7.1.3 Germany

        7.1.4 France

        7.1.5 UK

        7.1.6 Italy

        7.1.7 Russia

    7.2 Europe Biosimilars by Type

    7.3 Europe Biosimilars by Application

    7.4 Europe Biosimilars by Company

8 Asia Pacific

    8.1 Asia Pacific Biosimilars by Countries

        8.1.1 Asia Pacific Biosimilars Sales by Countries

        8.1.2 Asia Pacific Biosimilars Revenue by Countries

        8.1.3 China

        8.1.4 Japan

        8.1.5 Korea

        8.1.6 India

        8.1.7 Australia

        8.1.8 Indonesia

        8.1.9 Malaysia

        8.1.10 Philippines

        8.1.11 Thailand

        8.1.12 Vietnam

        8.1.13 Singapore

    8.2 Asia Pacific Biosimilars by Type

    8.3 Asia Pacific Biosimilars by Application

    8.4 Asia Pacific Biosimilars by Company

9 Central & South America

    9.1 Central & South America Biosimilars by Countries

        9.1.1 Central & South America Biosimilars Sales by Countries

        9.1.2 Central & South America Biosimilars Revenue by Countries

        9.1.3 Brazil

    9.2 Central & South America Biosimilars by Type

    9.3 Central & South America Biosimilars by Application

    9.4 Central & South America Biosimilars by Company

10 Middle East and Africa

    10.1 Middle East and Africa Biosimilars by Countries

        10.1.1 Middle East and Africa Biosimilars Sales by Countries

        10.1.2 Middle East and Africa Biosimilars Revenue by Countries

        10.1.3 GCC Countries

        10.1.4 Turkey

        10.1.5 Egypt

        10.1.6 South Africa

    10.2 Middle East and Africa Biosimilars by Type

    10.3 Middle East and Africa Biosimilars by Application

    10.4 Middle East and Africa Biosimilars by Company

11 Company Profiles

    11.1 Pfizer

        11.1.1 Pfizer Company Details

        11.1.2 Company Description

        11.1.3 Sales, Revenue and Gross Margin of Biosimilars

        11.1.4 Biosimilars Product Description

        11.1.5 Recent Development

    11.2 Sandoz International GmbH

        11.2.1 Sandoz International GmbH Company Details

        11.2.2 Company Description

        11.2.3 Sales, Revenue and Gross Margin of Biosimilars

        11.2.4 Biosimilars Product Description

        11.2.5 Recent Development

    11.3 Teva Pharmaceuticals Industries

        11.3.1 Teva Pharmaceuticals Industries Company Details

        11.3.2 Company Description

        11.3.3 Sales, Revenue and Gross Margin of Biosimilars

        11.3.4 Biosimilars Product Description

        11.3.5 Recent Development

    11.4 Amgen Inc

        11.4.1 Amgen Inc Company Details

        11.4.2 Company Description

        11.4.3 Sales, Revenue and Gross Margin of Biosimilars

        11.4.4 Biosimilars Product Description

        11.4.5 Recent Development

    11.5 Biocon

        11.5.1 Biocon Company Details

        11.5.2 Company Description

        11.5.3 Sales, Revenue and Gross Margin of Biosimilars

        11.5.4 Biosimilars Product Description

        11.5.5 Recent Development

    11.6 Dr. Reddy’s Laboratories

        11.6.1 Dr. Reddy’s Laboratories Company Details

        11.6.2 Company Description

        11.6.3 Sales, Revenue and Gross Margin of Biosimilars

        11.6.4 Biosimilars Product Description

        11.6.5 Recent Development

    11.7 F. Hoffmann-La Roche

        11.7.1 F. Hoffmann-La Roche Company Details

        11.7.2 Company Description

        11.7.3 Sales, Revenue and Gross Margin of Biosimilars

        11.7.4 Biosimilars Product Description

        11.7.5 Recent Development

    11.8 Celltrion

        11.8.1 Celltrion Company Details

        11.8.2 Company Description

        11.8.3 Sales, Revenue and Gross Margin of Biosimilars

        11.8.4 Biosimilars Product Description

        11.8.5 Recent Development

    11.9 Samsung Bioepis

        11.9.1 Samsung Bioepis Company Details

        11.9.2 Company Description

        11.9.3 Sales, Revenue and Gross Margin of Biosimilars

        11.9.4 Biosimilars Product Description

        11.9.5 Recent Development

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    12.1 Market Opportunities and Drivers

    12.2 Market Challenges

    12.3 Market Risks/Restraints

    12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis

    13.1 Value Chain Analysis

        13.1.1 Typical Suppliers of Key Biosimilars Raw Material

        13.1.2 Biosimilars Customers

    13.2 Sales Channels Analysis

        13.2.1 Sales Channels Analysis

        13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix

    15.1 Research Methodology

        15.1.1 Methodology/Research Approach

            15.1.1.1 Research Programs/Design

            15.1.1.2 Market Size Estimation

            15.1.1.3 Market Breakdown and Data Triangulation

        15.1.2 Data Source

            15.1.2.1 Secondary Sources

            15.1.2.2 Primary Sources

    15.2 Author Details

    15.3 Disclaimer



Sidebar Menu